By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Morris Corporate Center III
400 Interpace Parkway
Parippany  New Jersey  07054  U.S.A.
Phone: 1-862-261-7000 Fax: n/a


Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.

"Twice As" Video

"Our Winning Way" Video

Key Statistics

Ownership: Public

Web Site: Actavis
Symbol: ACT


Company News
Actavis (ACT), Valeant (VRX) Win FDA Approval for VIBERZI to Treat IBS With Diarrhea 5/28/2015 5:34:07 AM
Actavis (ACT) Release: Infectious Disease Experts, Scientists And Clinicians Join Forces On SHARE ID To Accelerate The Battle Against Antibiotic-Resistant Infections 5/27/2015 10:26:12 AM
Actavis (ACT) Ordered to Keep Older Alzheimer’s Drug Namenda on the Market 5/26/2015 7:46:38 AM
Actavis (ACT) To Present At Bernstein's Thirty-First Annual Strategic Decisions Conference 2015 5/21/2015 7:10:51 AM
Actavis (ACT) Launches NAMZARIC (memantine hydrochloride Extended-Release And donepezil hydrochloride), A Fixed-Dose Combination Therapy For The Treatment Of Moderate To Severe Alzheimer's Disease 5/18/2015 6:38:26 AM
Actavis (ACT) To Present At UBS Global Healthcare Conference 2015 5/13/2015 10:34:57 AM
Actavis (ACT) Reports Exceptional Performance In First Quarter 2015 With 59% Increase In Net Revenue To $4.2 Billion And 23% Growth In Non-GAAP EPS To $4.30 5/11/2015 6:57:33 AM
Actavis (ACT) To Re-Launch Generic Pulmicort Respules Following Favorable Appeals Court Ruling 5/8/2015 6:18:26 AM
Actavis (ACT) And Medicines360 Announce Publication Of ACCESS IUS Efficacy And Safety Study Of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception 4/29/2015 6:32:13 AM
Actavis (ACT) Announces Topline Phase 3 Clinical Trial Results For Single-Dose DALVANCE (Dalbavancin) In The Treatment Of ABSSSI 4/24/2015 10:14:17 AM